E
MetaVia Inc.
MTVA
$1.37
-$0.01-0.73%
E
Sell
1/26/2024Upgraded
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to E+ from E on 1/26/2024 due to an increase in the volatility index and total return index.
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to E+ from E on 1/26/2024 due to an increase in the volatility index and total return index.
E
Sell
1/10/2024Downgrade
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E from E+ on 1/10/2024 due to a decline in the volatility index.
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E from E+ on 1/10/2024 due to a decline in the volatility index.
E
Sell
12/12/2023Upgraded
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to E+ from E on 12/12/2023 due to an increase in the volatility index and total return index.
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to E+ from E on 12/12/2023 due to an increase in the volatility index and total return index.
E
Sell
11/27/2023Downgrade
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E from E+ on 11/27/2023 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.0181 to -$0.094, operating cash flow declined 37.6% from -$2.05M to -$2.81M, and EBIT declined 2.29% from -$3.81M to -$3.89M.
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E from E+ on 11/27/2023 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.0181 to -$0.094, operating cash flow declined 37.6% from -$2.05M to -$2.81M, and EBIT declined 2.29% from -$3.81M to -$3.89M.
E
Sell
11/20/2023Upgraded
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to E+ from E on 11/20/2023 due to an increase in the volatility index.
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to E+ from E on 11/20/2023 due to an increase in the volatility index.
E
Sell
11/3/2023Downgrade
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E from E+ on 11/3/2023 due to a decline in the volatility index.
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E from E+ on 11/3/2023 due to a decline in the volatility index.
E
Sell
10/2/2023Upgraded
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to E+ from E on 10/2/2023 due to an increase in the volatility index.
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to E+ from E on 10/2/2023 due to an increase in the volatility index.
E
Sell
9/15/2023Downgrade
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E from E+ on 9/15/2023 due to a decline in the volatility index.
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E from E+ on 9/15/2023 due to a decline in the volatility index.
E
Sell
3/14/2023Downgrade
MetaVia Inc. (MTVA) was downgraded to E+ from D- on 03/14/2023.
MetaVia Inc. (MTVA) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
MetaVia Inc. (MTVA) was upgraded to D- from E+ on 02/23/2023.
MetaVia Inc. (MTVA) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index and total return index.
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index and total return index.
D
Sell
12/15/2022Downgrade
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to D- from D on 12/15/2022 due to a decline in the volatility index.
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to D- from D on 12/15/2022 due to a decline in the volatility index.
D
Sell
11/29/2022Upgraded
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D from D- on 11/29/2022 due to an increase in the growth index, volatility index and valuation index. Operating cash flow increased 13.18% from -$2.72M to -$2.36M, earnings per share increased from -$3.7166 to -$3.5029, and EBIT increased 3.57% from -$3.22M to -$3.1M.
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D from D- on 11/29/2022 due to an increase in the growth index, volatility index and valuation index. Operating cash flow increased 13.18% from -$2.72M to -$2.36M, earnings per share increased from -$3.7166 to -$3.5029, and EBIT increased 3.57% from -$3.22M to -$3.1M.
D
Sell
8/15/2022Downgrade
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to D- from D on 8/15/2022 due to a decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.1078 to -$0.1239, EBIT declined 11.97% from -$2.88M to -$3.22M, and the quick ratio declined from 7.73 to 7.08.
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to D- from D on 8/15/2022 due to a decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.1078 to -$0.1239, EBIT declined 11.97% from -$2.88M to -$3.22M, and the quick ratio declined from 7.73 to 7.08.
D
Sell
8/10/2022Upgraded
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D from D- on 8/10/2022 due to an increase in the volatility index.
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D from D- on 8/10/2022 due to an increase in the volatility index.
D
Sell
7/25/2022Downgrade
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to D- from D on 7/25/2022 due to a decline in the volatility index.
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to D- from D on 7/25/2022 due to a decline in the volatility index.
D
Sell
6/27/2022Upgraded
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D from D- on 6/27/2022 due to an increase in the volatility index.
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D from D- on 6/27/2022 due to an increase in the volatility index.
D
Sell
6/10/2022Downgrade
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to D- from D on 6/10/2022 due to a decline in the volatility index.
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to D- from D on 6/10/2022 due to a decline in the volatility index.
D
Sell
5/23/2022Upgraded
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D from D- on 5/23/2022 due to an increase in the growth index. Earnings per share increased from -$0.173 to -$0.1078, and EBIT increased 37.2% from -$4.58M to -$2.88M.
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D from D- on 5/23/2022 due to an increase in the growth index. Earnings per share increased from -$0.173 to -$0.1078, and EBIT increased 37.2% from -$4.58M to -$2.88M.
D
Sell
5/5/2022Upgraded
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index and valuation index.
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D- from E+ on 5/5/2022 due to an increase in the volatility index and valuation index.
E
Sell
4/20/2022Downgrade
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E+ from D- on 4/20/2022 due to a decline in the growth index, total return index and volatility index. EBIT declined 32.16% from -$3.46M to -$4.58M, operating cash flow declined 15.64% from -$2.51M to -$2.9M, and earnings per share declined from -$0.16 to -$0.173.
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E+ from D- on 4/20/2022 due to a decline in the growth index, total return index and volatility index. EBIT declined 32.16% from -$3.46M to -$4.58M, operating cash flow declined 15.64% from -$2.51M to -$2.9M, and earnings per share declined from -$0.16 to -$0.173.
D
Sell
11/18/2021Upgraded
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D- from E+ on 11/18/2021 due to an increase in the growth index. Operating cash flow increased 30.11% from -$3.59M to -$2.51M, EBIT increased 11.77% from -$3.93M to -$3.46M, and earnings per share increased from -$0.1766 to -$0.16.
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D- from E+ on 11/18/2021 due to an increase in the growth index. Operating cash flow increased 30.11% from -$3.59M to -$2.51M, EBIT increased 11.77% from -$3.93M to -$3.46M, and earnings per share increased from -$0.1766 to -$0.16.
E
Sell
11/8/2021Downgrade
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E+ from D- on 11/8/2021 due to a decline in the growth index, total return index and solvency index. The quick ratio declined from 13.81 to 8.04, EBIT declined 17.9% from -$3.33M to -$3.93M, and earnings per share declined from -$0.1538 to -$0.1766.
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E+ from D- on 11/8/2021 due to a decline in the growth index, total return index and solvency index. The quick ratio declined from 13.81 to 8.04, EBIT declined 17.9% from -$3.33M to -$3.93M, and earnings per share declined from -$0.1538 to -$0.1766.
D
Sell
6/2/2021Downgrade
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to D- from D on 6/2/2021 due to a decline in the total return index and volatility index.
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to D- from D on 6/2/2021 due to a decline in the total return index and volatility index.
D
Sell
5/18/2021Upgraded
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D from E+ on 5/18/2021 due to a substantial increase in the growth index, solvency index and valuation index. The quick ratio increased from 2.73 to 13.81, and earnings per share increased from -$1.185 to -$0.1538.
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D from E+ on 5/18/2021 due to a substantial increase in the growth index, solvency index and valuation index. The quick ratio increased from 2.73 to 13.81, and earnings per share increased from -$1.185 to -$0.1538.
E
Sell
4/16/2021Downgrade
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E+ from D- on 4/16/2021 due to a decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.1859 to -$1.185, operating cash flow declined 20.16% from -$1.95M to -$2.35M, and the quick ratio declined from 3.42 to 2.73.
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E+ from D- on 4/16/2021 due to a decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.1859 to -$1.185, operating cash flow declined 20.16% from -$1.95M to -$2.35M, and the quick ratio declined from 3.42 to 2.73.
D
Sell
3/26/2021Upgraded
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D- from E+ on 3/26/2021 due to an increase in the total return index, volatility index and valuation index.
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D- from E+ on 3/26/2021 due to an increase in the total return index, volatility index and valuation index.
E
Sell
1/21/2021Downgrade
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E+ from D- on 1/21/2021 due to a decline in the volatility index and total return index.
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E+ from D- on 1/21/2021 due to a decline in the volatility index and total return index.
D
Sell
1/6/2021Upgraded
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D- from E+ on 1/6/2021 due to an increase in the volatility index and total return index.
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D- from E+ on 1/6/2021 due to an increase in the volatility index and total return index.
E
Sell
11/16/2020Downgrade
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E+ from D- on 11/16/2020 due to a large decline in the growth index, total return index and volatility index. EBIT declined 27.93% from -$2.39M to -$3.06M, and earnings per share declined from -$0.1462 to -$0.1859.
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E+ from D- on 11/16/2020 due to a large decline in the growth index, total return index and volatility index. EBIT declined 27.93% from -$2.39M to -$3.06M, and earnings per share declined from -$0.1462 to -$0.1859.
D
Sell
9/1/2020Upgraded
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D- from E on 9/1/2020 due to an increase in the growth index, solvency index and valuation index. The quick ratio increased from 2.64 to 4.57, earnings per share increased from -$0.3018 to -$0.1462, and EBIT increased 49.63% from -$4.75M to -$2.39M.
NeuroBo Pharmaceuticals, Inc. (NRBO) was upgraded to D- from E on 9/1/2020 due to an increase in the growth index, solvency index and valuation index. The quick ratio increased from 2.64 to 4.57, earnings per share increased from -$0.3018 to -$0.1462, and EBIT increased 49.63% from -$4.75M to -$2.39M.
E
Sell
6/2/2020Upgraded
MetaVia Inc. (MTVA) was upgraded to E from E- on 06/02/2020.
MetaVia Inc. (MTVA) was upgraded to E from E- on 06/02/2020.
E
Sell
4/3/2020Downgrade
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E- from E on 4/3/2020 due to a decline in the valuation index and growth index. Earnings per share declined from -$0.4829 to -$1.8163, and operating cash flow declined 5.79% from -$1.21M to -$1.28M.
NeuroBo Pharmaceuticals, Inc. (NRBO) was downgraded to E- from E on 4/3/2020 due to a decline in the valuation index and growth index. Earnings per share declined from -$0.4829 to -$1.8163, and operating cash flow declined 5.79% from -$1.21M to -$1.28M.
E
Sell
3/26/2020None
MetaVia Inc. (MTVA) was downgraded to E from U on 03/26/2020.
MetaVia Inc. (MTVA) was downgraded to E from U on 03/26/2020.
NASDAQ
04/10/2025 3:59PM Eastern
Quotes delayed
